NEWS IN BRIEF

LabConnect completes phase one of expansion to up PBMC capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Jezperklauzen)
(Image: Jezperklauzen)
LabConnect has completed phase one of three to increase its capacity for peripheral blood mononuclear cell (PBMC) processing at its facility in Johnson City, TN.

According to the central laboratory and support services provider, the planned expansion, which will happen in three phases, comes in response to its 30% growth since 2017.

Phase one – yesterday announced as completed – expanded the LabConnect’s clinical sample kit-building and storage capabilities by more than 11,000 square feet.

Phase two of the expansion will add more offices and project management space, according to the company. In the third phase, the company will build out its PBMC laboratory capabilities.

The expansion is expected to be completed in September 2018.

Related topics: Clinical Development

Related news

Follow us

Products

View more

Webinars